

November 3, 2022

Dipal Doshi
Chief Executive Officer
Entrada Therapeutics, Inc.
6 Tide Street
Boston, MA 02210

Therapeutics, Inc.
Statement on Form S-3
2022

Re: Entrada
Registration
Filed November 1,
File No. 333-268099

Dear Dipal Doshi:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact
Christine Westbrook at 202-551-5019 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

cc:

Sarah Ashfaq, Esq.